Topics:

RAS Mutations Enhance Chemotherapy in AML

RAS Mutations Enhance Chemotherapy in AML

Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.

 
Loading comments...
Please Wait 20 seconds or click here to close